Compare NEULAND LABS with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS AJANTA PHARMA NEULAND LABS/
AJANTA PHARMA
 
P/E (TTM) x 53.9 28.4 190.0% View Chart
P/BV x 4.1 7.9 51.7% View Chart
Dividend Yield % 0.1 0.4 19.8%  

Financials

 NEULAND LABS   AJANTA PHARMA
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
AJANTA PHARMA
Mar-19
NEULAND LABS/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs7541,422 53.0%   
Low Rs247898 27.6%   
Sales per share (Unadj.) Rs594.5233.5 254.6%  
Earnings per share (Unadj.) Rs12.644.0 28.7%  
Cash flow per share (Unadj.) Rs37.052.2 71.0%  
Dividends per share (Unadj.) Rs2.009.00 22.2%  
Dividend yield (eoy) %0.40.8 51.5%  
Book value per share (Unadj.) Rs553.4255.1 216.9%  
Shares outstanding (eoy) m12.8388.02 14.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.85.0 17.0%   
Avg P/E ratio x39.626.4 150.2%  
P/CF ratio (eoy) x13.522.2 60.8%  
Price / Book Value ratio x0.94.5 19.9%  
Dividend payout %15.820.5 77.3%   
Avg Mkt Cap Rs m6,421102,081 6.3%   
No. of employees `0001.36.8 18.9%   
Total wages/salary Rs m1,2364,307 28.7%   
Avg. sales/employee Rs Th5,949.43,022.6 196.8%   
Avg. wages/employee Rs Th963.8633.4 152.2%   
Avg. net profit/employee Rs Th126.4569.1 22.2%   
INCOME DATA
Net Sales Rs m7,62720,554 37.1%  
Other income Rs m39211 18.4%   
Total revenues Rs m7,66620,765 36.9%   
Gross profit Rs m1,0195,664 18.0%  
Depreciation Rs m313721 43.4%   
Interest Rs m21612 1,859.7%   
Profit before tax Rs m5295,143 10.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3671,273 28.8%   
Profit after tax Rs m1623,870 4.2%  
Gross profit margin %13.427.6 48.5%  
Effective tax rate %69.424.8 280.3%   
Net profit margin %2.118.8 11.3%  
BALANCE SHEET DATA
Current assets Rs m5,15211,812 43.6%   
Current liabilities Rs m3,5763,776 94.7%   
Net working cap to sales %20.739.1 52.8%  
Current ratio x1.43.1 46.1%  
Inventory Days Days10577 135.8%  
Debtors Days Days9182 111.4%  
Net fixed assets Rs m3,96914,398 27.6%   
Share capital Rs m129175 73.5%   
"Free" reserves Rs m6,97122,277 31.3%   
Net worth Rs m7,10022,452 31.6%   
Long term debt Rs m7747 11,722.7%   
Total assets Rs m12,31026,962 45.7%  
Interest coverage x3.5444.3 0.8%   
Debt to equity ratio x0.10 37,072.5%  
Sales to assets ratio x0.60.8 81.3%   
Return on assets %3.114.4 21.3%  
Return on equity %2.317.2 13.2%  
Return on capital %9.523.0 41.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,18710,682 48.6%   
Fx outflow Rs m1,5932,102 75.8%   
Net fx Rs m3,5948,580 41.9%   
CASH FLOW
From Operations Rs m5733,748 15.3%  
From Investments Rs m-487-2,228 21.8%  
From Financial Activity Rs m-55-1,475 3.7%  
Net Cashflow Rs m3345 72.1%  

Share Holding

Indian Promoters % 36.3 73.8 49.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 63.7 1.6 4,111.6%  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 17.0 374.9%  
Shareholders   12,705 20,968 60.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare NEULAND LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


May 12, 2021 03:36 PM

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 5-YR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS